Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man.

@article{Hildebrand1990EffectsOA,
  title={Effects of a cholecystokinin receptor antagonist on intestinal phase of pancreatic and biliary responses in man.},
  author={P. Llody Hildebrand and Christoph Beglinger and Klaus Gyr and Jeroen J. Jansen and Lucio Claudio Rovati and Marcel Z{\"u}rcher and Cornelis B. H. W. Lamers and Ivo Setnikar and Gr{\'e}goire Stalder},
  journal={The Journal of clinical investigation},
  year={1990},
  volume={85 3},
  pages={640-6}
}
The present study was designed (a) to characterize the activity of loxiglumide as a peripheral cholecystokinin (CCK) antagonist in healthy human subjects, and (b) to determine whether CCK is a physiologic regulator of the intestinal phase of meal-stimulated exocrine pancreatic and biliary secretions in man. Intravenous loxiglumide (22 mumol/kg per h) was highly potent in antagonizing CCK8-induced pancreatic enzyme and bile acid secretion as well as pancreatic polypeptide release. The potency… CONTINUE READING